E x p l o r i n g
t h e
c u t t i n g
e d g e
o f
n e u r o s c i e n c e
Ignis
Ignis Therapeutics was established at the end of 2020. As a biotech company dedicated to central nervous system (CNS) diseases, we are committed to transforming cutting-edge science into innovative solutions that benefit patients.
2020
Founded
$185
M
Series A financing
100+
Employees
20+
Pipelines
Core Business and Therapeutic Area
Central Nervous System (CNS) diseases
Epilepsy
Excessive
Daytime
Sleepiness
Daytime
Sleepiness
Insomnia
Parkinson's
Disease
Disease
Migraine
Attention Deficit
Hyperactivity
Disorder
Hyperactivity
Disorder
Major
Depressive
Disorder
Depressive
Disorder
Schizophrenia
Neuropathic
Pain
Pain
Alzheimer's
Disease
Disease
Covering entire pathway, providing holistic solutions
Business Model
01.
Leveraging licensed-in products, in-house R&D and mature products, we deliver better and sustainable therapeutic solutions to patients.
02.
Fostering an open ecosystem, we provide comprehensive support for patients and their caregivers.
03.
Covering the entire value chain, from R&D, clinical development, registration, manufacturing, supply chain, and commercialization, we ensure seamless integration for optimized healthcare delivery.
Team
CEO
Eileen Long, M.D.
Chief Executive Officer & Chief Medical Officer
• 25 years of management experience in multinational pharmaceutical companies.
• Former General Manager of Sanofi China's Central Nervous System (CNS) Division, establishing the largest CNS BU among multinational pharmaceutical companies in China.
• Extensive commercial operations expertise with multiple roles at leading MNCs such as Novartis, Bristol-Myers Squibb, and Wyeth, covering areas including Marketing, Medical Affairs, and Business Unit Management.
• M.D., Peking Union Medical College; MM, China Europe International Business School (CEIBS).
• Former General Manager of Sanofi China's Central Nervous System (CNS) Division, establishing the largest CNS BU among multinational pharmaceutical companies in China.
• Extensive commercial operations expertise with multiple roles at leading MNCs such as Novartis, Bristol-Myers Squibb, and Wyeth, covering areas including Marketing, Medical Affairs, and Business Unit Management.
• M.D., Peking Union Medical College; MM, China Europe International Business School (CEIBS).
Board of Directors
Leon Chen, Ph.D.
Chairman
• 30+ years of experience in drug development, management consulting and venture investment in US, Europe and China.
• Founding Managing Partner and CEO of 6 Dimensions Capital.
• Former Partner of Fidelity Asia Ventures, Managing Partner of BioVeda China, with previous tenures at McKinsey & Company, Ernst & Young LLP, Schering-Plough.
• B.Sc., Peking University; Ph.D., Catholic University of Louvain; Postdoc, Massachusetts Institute of Technology (MIT) .
• Founding Managing Partner and CEO of 6 Dimensions Capital.
• Former Partner of Fidelity Asia Ventures, Managing Partner of BioVeda China, with previous tenures at McKinsey & Company, Ernst & Young LLP, Schering-Plough.
• B.Sc., Peking University; Ph.D., Catholic University of Louvain; Postdoc, Massachusetts Institute of Technology (MIT) .
Eileen Long, M.D.
Director
Qin Xie, Ph.D.
Director
Ji Young Jung
Director
Jin Kang Chang, Ph.D.
Director
Management Team
Kevin Fang, Ph.D.
Chief Scientific Officer & Head of Neuroscience Innovation Center
• 30 years of leading CNS drug discovery and development experience.
• Inventor of over 50 US patents, led many research projects into clinic, including CNS marketed drugs.
• Formerly worked at Kanghong Pharmaceutical and Sunovion. Former Executive Committee Member of the Chinese American BioMedical Association(CABA), and President.
• Former Executive Committee Member of the Sino-American Pharmaceutical Professionals Association–New England (SAPA-NE).
• Ph.D., Massachusetts Institute of Technology (MIT) ; National High-Level Talent.
• Inventor of over 50 US patents, led many research projects into clinic, including CNS marketed drugs.
• Formerly worked at Kanghong Pharmaceutical and Sunovion. Former Executive Committee Member of the Chinese American BioMedical Association(CABA), and President.
• Former Executive Committee Member of the Sino-American Pharmaceutical Professionals Association–New England (SAPA-NE).
• Ph.D., Massachusetts Institute of Technology (MIT) ; National High-Level Talent.
Junliang Hao, Ph.D.
Senior VP of Chemistry
• Over 20 years experience in drug discovery and development within the Central Nervous System (CNS) field.
• Holds multiple international patents and has published numerous high-impact academic papers, driving several innovative compounds into clinical stages.
• Formerly worked at Eli Lilly (USA).
• Ph.D. in Organic Chemistry, University of Minnesota, USA; Completed postdoctoral fellowships at The Scripps Research Institute and Harvard University.
• Holds multiple international patents and has published numerous high-impact academic papers, driving several innovative compounds into clinical stages.
• Formerly worked at Eli Lilly (USA).
• Ph.D. in Organic Chemistry, University of Minnesota, USA; Completed postdoctoral fellowships at The Scripps Research Institute and Harvard University.
Yishan Sun, Ph.D.
VP of Biology
• 15+ years of experience in drug discovery and translational research, across the fields of neuropsychiatric and neurodegenerative disorders.
• Led multiple first-in-class discovery projects to IND approval.
• Formerly worked at Novartis Institutes for BioMedical Research (US) and SciNeuro Pharmaceuticals (US).
• Ph.D. in Neuroscience from the University of Iowa; Completed postdoctoral fellowships at Stanford University.
• Led multiple first-in-class discovery projects to IND approval.
• Formerly worked at Novartis Institutes for BioMedical Research (US) and SciNeuro Pharmaceuticals (US).
• Ph.D. in Neuroscience from the University of Iowa; Completed postdoctoral fellowships at Stanford University.
Qiang Li
Chief Operating Officer
• 15+ years of project management and team management experience in the pharmaceutical industry.
• Extensive experience in multi-therapeutic product management (CNS, Anti-Infective, Pain, Cardiovascular field. Previously managed teams of over 250 members, driving the successful launch of multiple new products and the execution of Phase IV clinical studies.
• Formerly worked at multinational pharmaceutical companies including Pfizer and Sanofi.
• BS, China Pharmaceutical University; MBA, Southwest Jiaotong University.
• Extensive experience in multi-therapeutic product management (CNS, Anti-Infective, Pain, Cardiovascular field. Previously managed teams of over 250 members, driving the successful launch of multiple new products and the execution of Phase IV clinical studies.
• Formerly worked at multinational pharmaceutical companies including Pfizer and Sanofi.
• BS, China Pharmaceutical University; MBA, Southwest Jiaotong University.
Vicky Zhang
Chief Financial Officer
• 10+ years of IPO, M&A, licensing, equity/equity linked transactions, catalyzing HKEX and Nasdaq debuts across biotech and life-science arenas.
• Former CFO leading Adlai Nortye Biopharma (ANL.Nasdaq)’s US listing.
• Former executive director at Goldman Sachs Asia.
• MSc in Financial Economics at Oxford University, United Kingdom.
• Former CFO leading Adlai Nortye Biopharma (ANL.Nasdaq)’s US listing.
• Former executive director at Goldman Sachs Asia.
• MSc in Financial Economics at Oxford University, United Kingdom.
Katy Ma
Head of Human Resources and Administration
• 10+ years of experience in human resources management.
• Including but not limited to: Organizational Development, Talent Development, Compensation & Benefits, Performance Management, Recruitment, Training, and Employee Relations.
• Formerly worked at WuXi AppTec.
• BA, Sichuan University.
• Including but not limited to: Organizational Development, Talent Development, Compensation & Benefits, Performance Management, Recruitment, Training, and Employee Relations.
• Formerly worked at WuXi AppTec.
• BA, Sichuan University.
Doreen Huang, Ph.D.
Head of Legal and Compliance
• 10+ years of experience in legal affairs and intellectual property management.
• Formerly worked at Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Graf von Westphalen (German Law Firm).
• Ph.D., Friedrich-Alexander-University Erlangen-Nuremberg, admitted to practice the law in New York State U.S. as attorney at law and holder of the Chinese Legal Professional Qualification Certificate.
• Formerly worked at Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Graf von Westphalen (German Law Firm).
• Ph.D., Friedrich-Alexander-University Erlangen-Nuremberg, admitted to practice the law in New York State U.S. as attorney at law and holder of the Chinese Legal Professional Qualification Certificate.
Partners
SK Biopharmaceuticals and its US subsidiary, SK Life Science, are global pharmaceutical leaders specializing in the research, development and commercialization of drugs for the central nervous system (CNS), oncology, and other fields. SK Biopharmaceuticals has its own sales network in US. The company has various drug molecules targeting at CNS disorders, including epilepsy. Ignis has entered into a licensing agreement and a long-term strategic partnership with SK Biopharmaceuticals, aimed at addressing the unmet clinical needs in the CNS field in China.
NeuroSigma is a Los Angeles, California-based bio-electronic medical device company developing technologies to transform medical practice and patients' lives. The company is commercializing the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA. Ignis signed a strategic collaboration agreement with NeuroSigma in 2022 to jointly advance the clinical development and application of this therapy in China.
Shanghai Institute of Biochemistry and Cell Biology (SIBCB) was one of the units of Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences. Since March 18th, 2020, SIBCB has been renamed to CAS Center for Excellence in Molecular Cell Science (CEMCS), a cross-disciplinary, multi-institutional organization founded by Chinese Academy of Sciences (CAS), which aims to consolidate existing research strength of CAS laboratories via the formation of collaborative research teams. The center holds a prestigious scientific and social reputation both domestically and internationally.
Jointly founded by the Chinese Academy of Sciences (CAS) and Shanghai Municipal People’s Government in 2013, Shanghai-Tech University aspires to be a small-scale, high-level, international university oriented towards research and innovation, for nurturing the next generation of innovative scientists, inventors, and entrepreneurs. On February 14, 2022, Shanghai-Tech joined the list of China’s World-Class Universities Project as the youngest university in that list.
Ignis has embarked on extensive collaboration with the CEMCS and Shanghai-Tech University in the development of novel antidepressant drugs.
"We anticipate collaborating with partners to unlock the full potential of innovations and jointly forge a blueprint for a vibrant, healthier future."
Address
46F, BM InterContinental Business Center, No.100 Yutong Road, Jing’an District, Shanghai, China
